TB-500 Dosage in the Research Literature

Doses in the literature, plainly stated

Published research has used Thymosin Beta-4 and TB-500 across a wide range of doses: from picogram amounts in cell culture assays, through microgram-per-kilogram doses in rodent injury models, up to gram-level intravenous doses in the human Phase I trials. These are research quantities in specific study designs — they are not validated human dosing recommendations, and no such recommendation exists for the TB-500 fragment. This page lists what each study actually used, the route, and what animal or human model it was tested in. It also covers what is known and not known about pharmacokinetics and why extrapolating animal doses to people is not supported by the published data.

TB-500 Quantities Used in Research Protocols

TB-500 dosage in published research spans an extremely wide range because the literature encompasses cell-culture assays (picogram concentrations), rodent in vivo models (microgram to milligram per kilogram), and human Phase I trials of the full-length protein (milligram to gram IV doses). The following table reflects documented research quantities — not clinical recommendations:

Animal model dosing is not equivalent to human dosing. Allometric scaling from rodent to human requires body surface area or pharmacokinetic modeling adjustments — this has not been published in peer-reviewed literature for TB-500 specifically.

This site describes research quantities only. 'How much TB-500 should I take?' is not a question this literature digest answers — that framing is not appropriate for a research compound without validated human pharmacokinetics.

TB-500 Dosing Frequency in the Literature

Preclinical administration schedules vary substantially by model and endpoint:

• Single-dose or short-course protocols appear in wound closure models (days to 2 weeks)
• Chronic protocols appear in muscle degeneration models: Spurney et al. (2010) administered 150 µg IP twice weekly for 6 months in mdx mice ^[16]
• Daily intraperitoneal administration appears in the NAFLD liver inflammation model at 12 mg/kg/day ^[21]
• The human Phase I trial by Ruff et al. (2010) evaluated 14-day daily IV dosing alongside single-dose ascending cohorts ^[9]

No validated human dosing frequency schedule exists for TB-500 or for Thymosin Beta-4 in musculoskeletal, cardiac, or neurological indications. The ophthalmic dry eye protocol (6× daily topical for 28 days) is disease-specific and was for a 0.1% Tβ4 eye drop formulation — not a systemic peptide ^[8].

Anecdotal community literature describes 2–3× weekly protocols. These are not derived from controlled clinical research.

TB-500 Half-Life and Clearance in Animal Models

Formal pharmacokinetic data for TB-500 (the 7-residue Ac-LKKTETQ fragment) in humans is absent from the peer-reviewed literature. The anti-doping detection methodology study by Ho et al. (2012) validated LC-MS/MS detection of TB-500 in equine urine and plasma at limits of 0.01 ng/mL and 0.02 ng/mL respectively, but did not characterize a plasma half-life ^[12].

For full-length Thymosin Beta-4 (Tβ4), the Phase I IV pharmacokinetic trial by Ruff et al. (2010) confirmed dose-proportional Cmax and AUC across doses of 42–1260 mg, with increasing half-life at higher IV doses — but specific half-life values were not published in the available abstract ^[9]. The Chinese Phase I study by Wang et al. (2021) similarly confirmed consistent terminal clearance across dose groups without accumulation on repeat dosing ^[10].

The practical implication: the published human pharmacokinetic data is for the 43-amino-acid protein administered intravenously at gram-range doses in a controlled research context. Extrapolating these values to the 7-residue synthetic fragment administered by other routes is not supported by published evidence.

The stability note in the research context: TB-500 as a lyophilized synthetic peptide is stable in powder form. Research preparations are reconstituted in bacteriostatic water or sterile saline for injectable use in animal models. Short peptide half-life has been cited as a limitation driving the engineered tandem tTB4 analog (Nguyen et al. 2025) with dual G-actin binding domains ^[20].

Routes of Administration in Preclinical Research

Research models have employed several administration routes:

Intraperitoneal (IP): The most common preclinical route in rodent models. Used in the skeletal muscle study (150 µg, mdx mice) ^[16], the NAFLD study (12 mg/kg/day) ^[21], and cardiac AAV delivery contexts ^[5].

Topical: Used in wound healing and corneal studies. The original wound re-epithelialization findings in rats used both topical and intraperitoneal administration ^[2]. The dry eye Phase 2 used 0.1% ophthalmic drops, 6× daily ^[8].

Local/intralesional: The medial collateral ligament study delivered Tβ4 via fibrin sealant placed directly in the ligament gap at 1 µg — a highly localized approach without systemic exposure ^[3].

Intravenous: The two human Phase I trials of full-length Tβ4 used IV administration. This is the only peer-reviewed route with human pharmacokinetic data ^[9][10].

Subcutaneous: The equine anti-doping literature identifies subcutaneous administration as the veterinary route; the detection methodology was validated in post-SC-administration samples ^[12].

Oral bioavailability of TB-500 has not been established in peer-reviewed studies. Oral peptide delivery faces proteolytic degradation in the GI tract — stomach acid and digestive enzymes cleave short peptide sequences efficiently. No peer-reviewed pharmacokinetic study has demonstrated meaningful oral bioavailability for TB-500 or Thymosin Beta-4.

Oral vs. Injectable Administration in Research

Most preclinical research administers TB-500/Tβ4 via subcutaneous, intramuscular, intraperitoneal, topical, or intravenous injection. Oral delivery of peptides is challenging: the GI tract's proteolytic environment degrades small peptide sequences before they reach systemic circulation at meaningful concentrations.

No peer-reviewed study has demonstrated oral bioavailability of TB-500 (Ac-LKKTETQ) in any species. Community discussion of oral TB-500 exists, but the pharmacokinetic rationale for oral absorption of a 7-amino-acid acetylated peptide at biologically relevant concentrations is not supported by published data.

The 2025 tandem tTB4 (Nguyen et al.) study addressed production efficiency via bacterial fermentation synthesis — a cost concern, not a bioavailability improvement. The compound in that study was administered topically to the cornea ^[20].

Reconstitution in Research Settings

The research literature describes reconstitution of lyophilized TB-500 and Tβ4 preparations in bacteriostatic water or sterile saline for injectable use in animal model research. Stability and optimal concentration vary by study protocol; no standardized clinical reconstitution guideline exists for the compound.

In anti-doping reference sample preparation (Ho et al. 2012), the compound was reconstituted for standard preparation in equine plasma and urine matrices for assay validation purposes ^[12].

This is descriptive of research laboratory practice. It is not a preparation instruction.

Onset of Effect in Preclinical Models

Animal studies report measurable tissue-repair markers within days to weeks, depending on the injury model and endpoint:

• Wound re-epithelialization: 42% improvement measured at day 4, 61% at day 7 in rat wound models ^[2]
• Ligament healing: histological and biomechanical improvement at 4 weeks vs. controls ^[3]
• Cardiac recovery: vascular and functional markers assessed at post-infarct intervals ranging from days (acute survival) to weeks (fibrosis outcomes) ^[4][5]
• Neurological (TBI): vascular density improvement measured at 35 days post-injury ^[8]

These are model-specific endpoints. No validated human onset data exists for TB-500 or for systemic Tβ4 in musculoskeletal, cardiac, or neurological indications.

TB-500 Clearance and Systemic Persistence

No peer-reviewed human pharmacokinetic data for TB-500 (Ac-LKKTETQ) specifically. For full-length Thymosin Beta-4, human Phase I IV data confirmed dose-proportional pharmacokinetics with no accumulation on 14-day repeat dosing at 42–1260 mg doses ^[9][10]. Specific half-life values were not published in available abstracts.

Detection windows for TB-500 in anti-doping contexts have been partially characterized in equine samples via LC-MS/MS (detection limits 0.01 ng/mL urine, 0.02 ng/mL plasma) ^[12], but human detection window data has not been published in peer-reviewed literature. At least one athlete has received a sanction from the Canadian Centre for Ethics in Sport for TB-500 use, indicating practical detection capability in human samples — but the underlying detection methodology for human samples is not publicly documented in peer-reviewed form.